Darbepoetin Alfa- (BNF) - Erythropoietins
Drug Name:
Darbepoetin Alfa- (BNF) - Erythropoietins
List Of Brands:
Indication Type Description:
Indication:
Ref- BNF (British National Formulary- March 2015)
Indications-
Symtomatic anaemia in adults with non-myeloid malignancies
receiving chemotherapy
Adverse Reaction:
Side effects
Odemia inpregnancy, injection site pain,
isolated reports of pure red cell aplasia, particularly following
subcutaneous administration in patients with chronic renal failure
(discontinue therapy)
Contra-Indications:
CONTRAINDICATIONS-
Pure red cell aplasia folllowing ertythropoitin therapy
uncontrolled hypersion, patients unable to receive
thrombopropyhlaxis.
avoid injections contain benzyl alcohol in neotates
Cautions
Hepatic impaitment-
manufacturer advices caution
Dosages/ Overdosage Etc:
Ref- BNF (British National Formulary- March 2015)
BRAND - ARANESP
MANUFACTURER - AMGEN
AMGEN LIMITED
TEL- (01223) 420 305
Indications-
Symtomatic anaemia in adults with non-myeloid malignancies
receiving chemotherapy
Dose-
symptomatic anaemia associted with chronic renal failure in patients
on dialysis
Addult and Child over 11 years by subcutaneous or intravenous injection
initially 450 nanograms /kg once weekly adjusted according to response
by approx.25% at intervals of at least 4 weeks.
maintenance dose given once weekly or once every 2 weeks
symptomatic anemia associated with chronic renal failure not on dialysis
Adult- and child over 11 years by subcutaneous or intravenous injection-
initially 450 nanograms /.kg once weekly
or by subcutaneous injection-
initially 750nanograms /kg once every 2 weeks, adjusted by response
by approx 25% at intervals of at least 4 weeks
maintenance dose- given subcutaneously or intravenously
once weekly or subcutaneously once every 2 weeks or
suncutaneously once every month
Pregnancy and lactation:
Pregnancy-
no evidence of harm in animal stidies- manufacture advices caution
Breast feeding-
manufacturer advices avoid- no informaion available